Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:56:18 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:DERM - JOURNEY MEDICAL CORPORATION - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DERM - Q5.02.00·3.701.13.48-0.10-2.8102.53383403.51  3.64  3.408.11  1.0219:03:24Mar 2115 min RT 2¢

Recent Trades - Last 10 of 340
Time ETExPriceChangeVolume
19:03:24Q3.41-0.1715
19:03:24Q3.40-0.18226
19:03:24Q3.40-0.18674
16:00:01Q3.48-0.10100
16:00:01Q3.48-0.102
16:00:01Q3.48-0.101,228
16:00:01Q3.48-0.101,447
16:00:01Q3.48-0.10158
16:00:01Q3.48-0.10143
16:00:01Q3.48-0.1033

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-21 16:01U:DERMNews ReleaseJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
2024-03-18 08:31U:DERMNews ReleaseJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
2024-03-15 08:30U:DERMNews ReleaseJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
2024-03-13 08:30U:DERMNews ReleaseJourney Medical Corporation to Participate in the 36th Annual ROTH Conference
2024-03-11 08:31U:DERMNews ReleaseJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
2024-01-05 08:30U:DERMNews ReleaseJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
2024-01-02 16:06U:DERMNews ReleaseJourney Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
2023-12-06 08:01U:DERMNews ReleaseJourney Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
2023-11-07 16:01U:DERMNews ReleaseJourney Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-01 08:00U:DERMNews ReleaseJasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
2023-10-31 08:30U:DERMNews ReleaseJourney Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
2023-10-20 08:31U:DERMNews ReleaseJourney Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn ‚ ® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
2023-09-06 08:00U:DERMNews ReleaseJourney Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza ‚ ® in South Korea and Other Asian Nations
2023-08-14 16:02U:DERMNews ReleaseFortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-08 16:02U:DERMNews ReleaseJourney Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-02 16:02U:DERMNews ReleaseJourney Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
2023-07-19 08:30U:DERMNews ReleaseJourney Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
2023-07-11 08:30U:DERMNews ReleaseJourney Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
2023-07-03 08:00U:DERMNews ReleaseJourney Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul
2023-06-13 08:31U:DERMNews ReleaseJourney Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects